Sanofi-Aventis (SNY) continues to work on expanding its oncology portfolio with the company recently entering into an agreement to acquire TargaGen Inc. TargaGen, a privately-held US biopharmaceutical company, is focused on the development of candidates for the treatment of certain types of leukemia, lymphoma and other hematological malignancies and blood disorders. Deal Could be Worth $560M Per [...] (SNY) Sanofi-Aventis Announces Agreement to Acquire TargaGen